Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 747 results
Found 747 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

R

Rodriguez B, Asmuth DM, Matining RM, et al. "Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial." J. Acquir. Immune Defic. Syndr.. 2013;64(4):351-9.
F Romo T, Smeaton LM, Campbell TB, et al. "Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175)." HIV Clin Trials. 2014;15(6):246-60.
Rosenberg ES, Graham BS, Chan ES, et al. "Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection." PLoS ONE. 2010;5(5):e10555.
Rosenkranz SL, Yarasheski KE, Para MF, Reichman RC, Morse GD. "Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic Analysis." Metab Syndr Relat Disord. 2007;5(2):163-73.
Rouabhia M, Semlali A, Chandra J, Mukherjee P, Chmielewski W, Ghannoum MA. "Disruption of the ECM33 gene in Candida albicans prevents biofilm formation, engineered human oral mucosa tissue damage and gingival cell necrosis/apoptosis." Mediators Inflamm.. 2012;2012:398207.
Rutstein SE, Hosseinipour MC, Weinberger M, et al. "Predicting resistance as indicator for need to switch from first-line antiretroviral therapy among patients with elevated viral loads: development of a risk score algorithm." BMC Infect. Dis.. 2016;16(1):280.

S

Saberi P, Neilands TB, Vittinghoff E, Johnson MO, Chesney M, Cohn SE. "Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS clinical trials group study participants." AIDS Patient Care STDS. 2015;29(3):111-6.
Sacktor N, Miyahara S, Deng L, et al. "Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial." Neurology. 2011;77(12):1135-42.
Sacktor N, Miyahara S, Evans S, et al. "Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment." J. Neurovirol.. 2014;20(6):620-6.
Safren SA, Hendriksen ES, Smeaton L, et al. "Quality of life among individuals with HIV starting antiretroviral therapy in diverse resource-limited areas of the world." AIDS Behav. 2012;16(2):266-77.
Safren SA, Biello KB, Smeaton L, et al. "Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial." PLoS ONE. 2014;9(8):e104178.
Saharia KK, Petrovas C, Ferrando-Martinez S, et al. "Tuberculosis Therapy Modifies the Cytokine Profile, Maturation State, and Expression of Inhibitory Molecules on Mycobacterium tuberculosis-Specific CD4+ T-Cells." PLoS ONE. 2016;11(7):e0158262.
D Salantes B, Zheng Y, Mampe F, et al. "HIV-1 latent reservoir size and diversity are stable following brief treatment interruption." J. Clin. Invest.. 2018;128(7):3102-3115.
Sandler NG, Zhang X, Bosch RJ, et al. "Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection." J. Infect. Dis.. 2014;210(10):1549-54.
Sattler FR, Rajicic N, Mulligan K, et al. "Evaluation of high-protein supplementation in weight-stable HIV-positive subjects with a history of weight loss: a randomized, double-blind, multicenter trial." Am. J. Clin. Nutr.. 2008;88(5):1313-21.
Sattler FR, Chelliah D, Wu X, et al. "Biomarkers Associated with Death After Initiating Treatment for Tuberculosis and HIV in Patients with Very Low CD Cells." Pathog Immun. 2018;3(1):46-62.
Sax PE, Tierney C, Collier AC, et al. "Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results." J. Infect. Dis.. 2011;204(8):1191-201.
Sax PE, Sloan CE, Schackman BR, et al. "Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164." HIV Clin Trials. 2010;11(5):248-59.
Sax PE, Komarow L, Finkelman MA, et al. "Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia." Clin. Infect. Dis.. 2011;53(2):197-202.
Sax PE, Tierney C, Collier AC, et al. "Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy." N. Engl. J. Med.. 2009;361(23):2230-40.
Schacker TW, Bosch RJ, Bennett K, et al. "Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIV." J. Acquir. Immune Defic. Syndr.. 2010;54(1):59-62.
Schackman BR, Haas DW, Park SS, X Li C, Freedberg KA. "Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice." Pharmacogenomics. 2015;16(18):2007-18.
Schackman BR, Scott CA, Sax PE, et al. "Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial." Clin. Infect. Dis.. 2007;45(8):1062-70.
Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. "Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095." J. Acquir. Immune Defic. Syndr.. 2007;46(5):547-54.
Schifitto G, Yiannoutsos CT, Simpson DM, et al. "A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy." J. Neurovirol.. 2006;12(4):328-31.
Schifitto G, Deng L, Yeh T-min, et al. "Clinical, laboratory, and neuroimaging characteristics of fatigue in HIV-infected individuals." J. Neurovirol.. 2011;17(1):17-25.
Schifitto G, Zhang J, Evans SR, et al. "A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment." Neurology. 2007;69(13):1314-21.
Schifitto G, Navia BA, Yiannoutsos CT, et al. "Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study." AIDS. 2007;21(14):1877-86.
Schifitto G, Yiannoutsos CT, Ernst T, et al. "Selegiline and oxidative stress in HIV-associated cognitive impairment." Neurology. 2009;73(23):1975-81.
Schnitzer ME, Lok JJ, Bosch RJ. "Double robust and efficient estimation of a prognostic model for events in the presence of dependent censoring." Biostatistics. 2016;17(1):165-77.

Pages